PE20080609A1 - Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3 - Google Patents

Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3

Info

Publication number
PE20080609A1
PE20080609A1 PE2007001117A PE2007001117A PE20080609A1 PE 20080609 A1 PE20080609 A1 PE 20080609A1 PE 2007001117 A PE2007001117 A PE 2007001117A PE 2007001117 A PE2007001117 A PE 2007001117A PE 20080609 A1 PE20080609 A1 PE 20080609A1
Authority
PE
Peru
Prior art keywords
methyl
oxazol
triazol
thio
fluoro
Prior art date
Application number
PE2007001117A
Other languages
English (en)
Spanish (es)
Inventor
Clare L Anderton
Sergio Bacchi
Stefania Beato
Franco Sartor
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37081324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080609(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2006/008314 external-priority patent/WO2007022980A1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20080609A1 publication Critical patent/PE20080609A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2007001117A 2006-08-21 2007-08-17 Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3 PE20080609A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0616574.0A GB0616574D0 (en) 2006-08-21 2006-08-21 Compounds
PCT/EP2006/008314 WO2007022980A1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives

Publications (1)

Publication Number Publication Date
PE20080609A1 true PE20080609A1 (es) 2008-07-26

Family

ID=37081324

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001117A PE20080609A1 (es) 2006-08-21 2007-08-17 Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3

Country Status (22)

Country Link
US (1) US20080058398A1 (enExample)
EP (1) EP2054054A1 (enExample)
JP (1) JP5315244B2 (enExample)
KR (1) KR101495362B1 (enExample)
CN (1) CN101528221B (enExample)
AR (1) AR062471A1 (enExample)
AU (1) AU2007287527B2 (enExample)
BR (1) BRPI0716454A2 (enExample)
CA (1) CA2661437A1 (enExample)
CL (1) CL2007002422A1 (enExample)
CO (1) CO6150139A2 (enExample)
CR (1) CR10638A (enExample)
EA (1) EA017917B1 (enExample)
GB (1) GB0616574D0 (enExample)
IL (1) IL196976A0 (enExample)
MA (1) MA30672B1 (enExample)
MX (1) MX2009001941A (enExample)
NO (1) NO20090834L (enExample)
PE (1) PE20080609A1 (enExample)
TW (1) TW200825074A (enExample)
WO (1) WO2008022994A1 (enExample)
ZA (1) ZA200900886B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1745040E (pt) * 2004-02-23 2010-03-08 Glaxo Group Ltd Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
EP1891056B1 (en) * 2005-06-14 2010-10-13 Glaxo Group Limited Novel compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
EP2007751B1 (en) * 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
WO2007113258A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260941B2 (ja) * 1998-11-09 2009-04-30 株式会社片山製薬所 アゼチジン−３−オール
EP1163217B1 (en) * 1999-03-15 2005-09-21 Novo Nordisk A/S New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
PT1745040E (pt) * 2004-02-23 2010-03-08 Glaxo Group Ltd Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina
SE526837C2 (sv) * 2004-02-24 2005-11-08 Kongsberg Automotive Asa Växelspakstransmission
WO2006011955A1 (en) * 2004-06-30 2006-02-02 Eli Lilly And Company 1 (indole-6-carbonyl-d-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine d-tartrate
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
EA200970211A1 (ru) 2009-08-28
JP5315244B2 (ja) 2013-10-16
BRPI0716454A2 (pt) 2014-03-04
CO6150139A2 (es) 2010-04-20
GB0616574D0 (en) 2006-09-27
KR101495362B1 (ko) 2015-02-24
KR20090052327A (ko) 2009-05-25
EP2054054A1 (en) 2009-05-06
AU2007287527B2 (en) 2013-01-31
TW200825074A (en) 2008-06-16
CA2661437A1 (en) 2008-02-28
MA30672B1 (fr) 2009-08-03
CL2007002422A1 (es) 2008-03-14
CN101528221B (zh) 2013-05-08
CR10638A (es) 2009-03-20
CN101528221A (zh) 2009-09-09
IL196976A0 (en) 2009-11-18
WO2008022994A1 (en) 2008-02-28
NO20090834L (no) 2009-03-19
MX2009001941A (es) 2009-03-05
JP2010501519A (ja) 2010-01-21
AR062471A1 (es) 2008-11-12
EA017917B1 (ru) 2013-04-30
ZA200900886B (en) 2011-05-25
US20080058398A1 (en) 2008-03-06
AU2007287527A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
PE20080609A1 (es) Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
EA201100049A1 (ru) Органические соединения
EA201100978A1 (ru) Схема приема агониста рецептора s1p
CL2008002199A1 (es) Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
EA201290103A1 (ru) Гетероциклические соединения и их использование
CL2008003822A1 (es) Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer.
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
CL2009001058A1 (es) Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
GEP20135961B (en) Fused ring compounds and usage thereof
PE20120812A1 (es) Compuestos vinil indazolilo
EA200970018A1 (ru) 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин в качестве соединения с сочетанием активности в отношении повторного захвата серотонина, 5-нт3 и 5-нт1а для лечения когнитивного нарушения
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
CL2013000768A1 (es) Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa.
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
NI201100024A (es) [ 4 - ( 5 - aminometil - 2 - fluoro - fenil ) - piperidin -1- il ] - [ 17-fluor0 - 1 - (2 - metoxi - etil ) - 4 - trifluorometoxi - 1h - indol - 3 - il] - metanona como un inhibidor de la triptasa de mastocitos.

Legal Events

Date Code Title Description
FC Refusal